Imaging of dopamine D2 and somatostatin receptors in vivo using single-photon emission tomography in a patient with a TSH/PRL-producing pituitary macroadenoma
Identifieur interne : 000269 ( Main/Exploration ); précédent : 000268; suivant : 000270Imaging of dopamine D2 and somatostatin receptors in vivo using single-photon emission tomography in a patient with a TSH/PRL-producing pituitary macroadenoma
Auteurs : RBID : ISTEX:259_1993_Article_BF00175168.pdfEnglish descriptors
- KwdEn :
Abstract
A 28-year-old man with a thyroid stimulating hormone/prolactin (TSH/PRL)-secreting pituitary macroadenoma is discussed in relation to dopamine D2 and somatostatin receptor single-photon emission tomography (SPET). The patient presented with decreased vision in the left eye as a result of a temporal visual field defect and with mild hyperthyroidism. Medical therapy was tried. A test dose of both octreotide and bromocriptine resulted in an acute reduction in serum levels of TSH, α-subunits and PRL, whereas there was no response to TRIAC. Somatostatin and dopamine D2 receptors were present on the tumour as visualised by SPET with the ligands indium-111 diethylene triamine penta-acetic acid (DTPA)-octreotide (111In-SMS) and iodine-123 iodobenzamide (123I-IBZM), respectively. Therefore, treatment with octreotide 150 μg t.i.d. subcutaneously and bromocriptine 10 mg b.i.d. orally was given for > 12 and > 6 weeks, respectively. Following this treatment the visual defects disappeared, although tumour size, as measured by CT scanning, and serum TSH levels did not decrease. SPET with 111In-SMS and 123I-IBZM after therapy revealed no change or a possible increase in somatostatin receptor binding potential and a possible decrease in dopamine D2 receptor binding potential. The lack of long-term effects of the medical treatment is discussed. It is concluded that a high somatostatin and dopamine D2 receptor binding potential in vivo in a TSH/PRL-producing adenoma does not necessarily predict a successful outcome of medical treatment.
DOI: 10.1007/BF00175168
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title>Imaging of dopamine D2 and somatostatin receptors in vivo using single-photon emission tomography in a patient with a TSH/PRL-producing pituitary macroadenoma</title><author><name>N. P. L. G. Verhoeff</name><affiliation wicri:level="1"><mods:affiliation>Department of Nuclear Medicine, Academic Medical Centre, Meibergdreef 9, NL-1105 AZ, Amsterdam Zuidoost, The Netherlands</mods:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Nuclear Medicine, Academic Medical Centre, Meibergdreef 9, NL-1105 AZ, Amsterdam Zuidoost</wicri:regionArea><wicri:noRegion>Amsterdam Zuidoost</wicri:noRegion></affiliation></author><author><name>F. J. Bemelman</name><affiliation wicri:level="1"><mods:affiliation>Department of Internal Medicine, Academic Medical Centre, Meibergdreef 9, NL-1105 AZ, Amsterdam Zuidoost, The Netherlands</mods:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Internal Medicine, Academic Medical Centre, Meibergdreef 9, NL-1105 AZ, Amsterdam Zuidoost</wicri:regionArea><wicri:noRegion>Amsterdam Zuidoost</wicri:noRegion></affiliation></author><author><name>W. M. Wiersinga</name><affiliation wicri:level="1"><mods:affiliation>Department of Endocrinology, Academic Medical Centre, Meibergdreef 9, NL-1105 AZ, Amsterdam Zuidoost, The Netherlands</mods:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Endocrinology, Academic Medical Centre, Meibergdreef 9, NL-1105 AZ, Amsterdam Zuidoost</wicri:regionArea><wicri:noRegion>Amsterdam Zuidoost</wicri:noRegion></affiliation></author><author><name>E. A. van Royen</name><affiliation wicri:level="1"><mods:affiliation>Department of Nuclear Medicine, Academic Medical Centre, Meibergdreef 9, NL-1105 AZ, Amsterdam Zuidoost, The Netherlands</mods:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Nuclear Medicine, Academic Medical Centre, Meibergdreef 9, NL-1105 AZ, Amsterdam Zuidoost</wicri:regionArea><wicri:noRegion>Amsterdam Zuidoost</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="RBID">ISTEX:259_1993_Article_BF00175168.pdf</idno><date when="1993">1993</date><idno type="doi">10.1007/BF00175168</idno><idno type="wicri:Area/Main/Corpus">000916</idno><idno type="wicri:Area/Main/Curation">000916</idno><idno type="wicri:Area/Main/Exploration">000269</idno></publicationStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Dopamine receptors</term><term>Pituitary adenoma</term><term>Prolactin</term><term>Single-photon emission tomography</term><term>Somatostatin receptors</term><term>Thyroid stimulating hormone</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="eng">A 28-year-old man with a thyroid stimulating hormone/prolactin (TSH/PRL)-secreting pituitary macroadenoma is discussed in relation to dopamine D2 and somatostatin receptor single-photon emission tomography (SPET). The patient presented with decreased vision in the left eye as a result of a temporal visual field defect and with mild hyperthyroidism. Medical therapy was tried. A test dose of both octreotide and bromocriptine resulted in an acute reduction in serum levels of TSH, α-subunits and PRL, whereas there was no response to TRIAC. Somatostatin and dopamine D2 receptors were present on the tumour as visualised by SPET with the ligands indium-111 diethylene triamine penta-acetic acid (DTPA)-octreotide (111In-SMS) and iodine-123 iodobenzamide (123I-IBZM), respectively. Therefore, treatment with octreotide 150 μg t.i.d. subcutaneously and bromocriptine 10 mg b.i.d. orally was given for > 12 and > 6 weeks, respectively. Following this treatment the visual defects disappeared, although tumour size, as measured by CT scanning, and serum TSH levels did not decrease. SPET with 111In-SMS and 123I-IBZM after therapy revealed no change or a possible increase in somatostatin receptor binding potential and a possible decrease in dopamine D2 receptor binding potential. The lack of long-term effects of the medical treatment is discussed. It is concluded that a high somatostatin and dopamine D2 receptor binding potential in vivo in a TSH/PRL-producing adenoma does not necessarily predict a successful outcome of medical treatment.</div></front></TEI><mods xsi:schemaLocation="http://www.loc.gov/mods/v3 file:///applis/istex/home/loadistex/home/etc/xsd/mods.xsd" version="3.4" istexId="a00f4937c1fdbcd0444f620244022702f44fbbe7"><titleInfo lang="eng"><title>Imaging of dopamine D2 and somatostatin receptors in vivo using single-photon emission tomography in a patient with a TSH/PRL-producing pituitary macroadenoma</title></titleInfo><name type="personal"><namePart type="given">N. P. L. G.</namePart><namePart type="family">Verhoeff</namePart><role><roleTerm type="text">author</roleTerm></role><affiliation>Department of Nuclear Medicine, Academic Medical Centre, Meibergdreef 9, NL-1105 AZ, Amsterdam Zuidoost, The Netherlands</affiliation></name><name type="personal"><namePart type="given">F. J.</namePart><namePart type="family">Bemelman</namePart><role><roleTerm type="text">author</roleTerm></role><affiliation>Department of Internal Medicine, Academic Medical Centre, Meibergdreef 9, NL-1105 AZ, Amsterdam Zuidoost, The Netherlands</affiliation></name><name type="personal"><namePart type="given">W. M.</namePart><namePart type="family">Wiersinga</namePart><role><roleTerm type="text">author</roleTerm></role><affiliation>Department of Endocrinology, Academic Medical Centre, Meibergdreef 9, NL-1105 AZ, Amsterdam Zuidoost, The Netherlands</affiliation></name><name type="personal"><namePart type="given">E. A.</namePart><namePart type="family">van Royen</namePart><role><roleTerm type="text">author</roleTerm></role><affiliation>Department of Nuclear Medicine, Academic Medical Centre, Meibergdreef 9, NL-1105 AZ, Amsterdam Zuidoost, The Netherlands</affiliation></name><typeOfResource>text</typeOfResource><genre>Case Reports</genre><genre>Original Paper</genre><originInfo><publisher>Springer-Verlag, Berlin/Heidelberg</publisher><dateCreated encoding="w3cdtf">1993-02-08</dateCreated><dateValid encoding="w3cdtf">2004-07-03</dateValid><copyrightDate encoding="w3cdtf">1993</copyrightDate></originInfo><language><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType></physicalDescription><abstract lang="eng">A 28-year-old man with a thyroid stimulating hormone/prolactin (TSH/PRL)-secreting pituitary macroadenoma is discussed in relation to dopamine D2 and somatostatin receptor single-photon emission tomography (SPET). The patient presented with decreased vision in the left eye as a result of a temporal visual field defect and with mild hyperthyroidism. Medical therapy was tried. A test dose of both octreotide and bromocriptine resulted in an acute reduction in serum levels of TSH, α-subunits and PRL, whereas there was no response to TRIAC. Somatostatin and dopamine D2 receptors were present on the tumour as visualised by SPET with the ligands indium-111 diethylene triamine penta-acetic acid (DTPA)-octreotide (111In-SMS) and iodine-123 iodobenzamide (123I-IBZM), respectively. Therefore, treatment with octreotide 150 μg t.i.d. subcutaneously and bromocriptine 10 mg b.i.d. orally was given for > 12 and > 6 weeks, respectively. Following this treatment the visual defects disappeared, although tumour size, as measured by CT scanning, and serum TSH levels did not decrease. SPET with 111In-SMS and 123I-IBZM after therapy revealed no change or a possible increase in somatostatin receptor binding potential and a possible decrease in dopamine D2 receptor binding potential. The lack of long-term effects of the medical treatment is discussed. It is concluded that a high somatostatin and dopamine D2 receptor binding potential in vivo in a TSH/PRL-producing adenoma does not necessarily predict a successful outcome of medical treatment.</abstract><subject lang="eng"><genre>Key words</genre><topic>Pituitary adenoma</topic><topic>Single-photon emission tomography</topic><topic>Dopamine receptors</topic><topic>Somatostatin receptors</topic><topic>Prolactin</topic><topic>Thyroid stimulating hormone</topic></subject><relatedItem type="series"><titleInfo type="abbreviated"><title>Eur J Nucl Med</title></titleInfo><titleInfo><title>European Journal of Nuclear Medicine</title><partNumber>Year: 1993</partNumber><partNumber>Volume: 20</partNumber><partNumber>Number: 6</partNumber></titleInfo><genre>Archive Journal</genre><originInfo><dateIssued encoding="w3cdtf">1993-06-01</dateIssued><copyrightDate encoding="w3cdtf">1993</copyrightDate></originInfo><subject usage="primary"><topic>Medicine & Public Health</topic><topic>Imaging / Radiology</topic><topic>Nuclear Medicine</topic></subject><identifier type="issn">0340-6997</identifier><identifier type="issn">Electronic: 1619-7089</identifier><identifier type="matrixNumber">259</identifier><identifier type="local">IssueArticleCount: 19</identifier><recordInfo><recordOrigin>Springer-Verlag, 1993</recordOrigin></recordInfo></relatedItem><identifier type="doi">10.1007/BF00175168</identifier><identifier type="matrixNumber">Art12</identifier><identifier type="local">BF00175168</identifier><accessCondition type="use and reproduction">MetadataGrant: OpenAccess</accessCondition><accessCondition type="use and reproduction">AbstractGrant: OpenAccess</accessCondition><accessCondition type="restriction on access">BodyPDFGrant: Restricted</accessCondition><accessCondition type="restriction on access">BodyHTMLGrant: Restricted</accessCondition><accessCondition type="restriction on access">BibliographyGrant: Restricted</accessCondition><accessCondition type="restriction on access">ESMGrant: Restricted</accessCondition><part><extent unit="pages"><start>555</start><end>561</end></extent></part><recordInfo><recordOrigin>Springer-Verlag, 1993</recordOrigin><recordIdentifier>259_1993_Article_BF00175168.pdf</recordIdentifier></recordInfo></mods></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=IndiumV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000269 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000269 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= *** parameter Area/wikiCode missing ***
|area= IndiumV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:259_1993_Article_BF00175168.pdf
|texte= Imaging of dopamine D2 and somatostatin receptors in vivo using single-photon emission tomography in a patient with a TSH/PRL-producing pituitary macroadenoma
}}
| This area was generated with Dilib version V0.5.81. |  |